Article

High-speed, high-resolution imaging of eye in sight

Fort Lauderdale, FL-Ultra-high-speed, ultra-high-resolution spectral-domain optical coherence tomography (SD-OCT) seems to have surpassed the slow-speed, low-resolution OCT and provides video images of the minute structural changes in the glaucomatous eye.

Teresa Chen, MD, demonstrated the capabilities of the instrument at the annual meeting of the Association for Research in Vision and Ophthalmology. Johannes F. de Boer, PhD, of Massachusetts General Hospital/Wellman Center for Photomedicine, Harvard Medical School, Boston, developed the SD-OCT.

How SD-OCT works

The previous-generation time-domain OCT differs from SD-OCT in that it has lower resolution (about 10 μm) and slower acquisition speed. Ultra-high-resolution time-domain OCT solved the problem of resolution but is extremely expensive. The titanium-sapphire laser source alone that is commonly used for ultra-high-resolution time-domain OCT can cost about $80,000, according to Dr. Chen. This is compared with about $8,000 for the superluminescent diode laser source.

The primary difference between SD-OCT and the previous OCT instruments is in the way information is processed, she explained. When the light returns from the eye and the reference mirror, it is processed by a spectrometer, hence the term SD-OCT. The data are then processed by Fourier transformation, and the data can then be used to create an image.

"For the first time we have a system that has simultaneous ultra-high resolution and ultra-high acquisition speed," Dr. Chen said. "It is more affordable and easy to maintain compared with ultra-high-resolution time-domain OCT."

Related Videos
2 experts are featured in this series.
Image credit: ©Ophthalmology Times
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Wendy Lee, MD, talks about functional oculoplastics and aesthetics at EnVision Summit 2025
1 expert is featured in this series.
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.